Santen Pharmaceutical Co., Ltd. held its 102nd Annual General Meeting of Shareholders for the fiscal year 2013 on June 25, 2014. The Meeting started at 10:00 a.m. and ended at 11:10 a.m. The number of shareholders attended was 253.

 

Matters reported	Business Report, Consolidated Financial Statements and Non-consolidated Financial Statements for the 102nd Business Term (April 1, 2013 to March 31, 2014) Independent Auditors Report and Corporate Auditors Report on the consolidated Financial Statements for the 102nd Business Term (April 1, 2013 to March 31, 2014)
Questions	We received questions regarding the following subjects from nine shareholders and responded in kind. Fiscal year 2014 earnings forecast Stance on potential acquisition targets Approach to long-term strategic vision Details on earnings at OTC pharmaceuticals business Matters concerning OTC eye drops Dividend payout plans Matters relevant to agreement with Merck & Co., Inc., Market shares and sales forecasts by region Japan glaucoma market: scale, share and other data Factors that curbed operating margins in fiscal year 2013
Matters resolved	Three items of business as described below were all resolved. Resolution (PDF: 24KB)PDF file.Page will open in a new window.
Questions	There was no question submitted by shareholders.